HOTCHKIS & WILEY's BIIB Position Overview
HOTCHKIS & WILEY (via Hotchkis & Wiley Capital Management LLC) currently holds 672,530 shares of Biogen Inc. (BIIB) worth $151.91 M, representing 0.43% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, HOTCHKIS & WILEY has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2026, adding 672,530 shares. Largest reduction occurred in Q2 2021, reducing 197,311 shares.
Analysis based on 13F filings available since 2013 Q2
HOTCHKIS & WILEY's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by HOTCHKIS & WILEY
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +672,530 | New Buy | 672,530 | $225.88 |
| Q4 2022 | -1,800 | Sold Out | 0 | $0.00 |
| Q3 2022 | +200 | Add 12.50% | 1,800 | $267.22 |
| Q2 2021 | -197,311 | Reduce 99.20% | 1,600 | $346.25 |
| Q1 2021 | -500 | Reduce 0.25% | 198,911 | $279.75 |
| Q4 2020 | -4,900 | Reduce 2.40% | 199,411 | $244.86 |
| Q3 2020 | -75,060 | Reduce 26.87% | 204,311 | $283.68 |
| Q2 2020 | -100 | Reduce 0.04% | 279,371 | $267.55 |
| Q1 2020 | +8,000 | Add 2.95% | 279,471 | $316.38 |
| Q4 2019 | +33,399 | Add 14.03% | 271,471 | $296.73 |
| Q3 2019 | +200 | Add 0.08% | 238,072 | $232.82 |
| Q2 2019 | -2,500 | Reduce 1.04% | 237,872 | $233.87 |
| Q1 2019 | -4,200 | Reduce 1.72% | 240,372 | $236.38 |
| Q4 2018 | -8,600 | Reduce 3.40% | 244,572 | $300.92 |
| Q3 2018 | -9,900 | Reduce 3.76% | 253,172 | $353.31 |
| Q2 2018 | -4,600 | Reduce 1.72% | 263,072 | $290.24 |
| Q1 2018 | -4,000 | Reduce 1.47% | 267,672 | $273.82 |
| Q4 2017 | -3,100 | Reduce 1.13% | 271,672 | $318.57 |
| Q3 2017 | -11,800 | Reduce 4.12% | 274,772 | $313.12 |
| Q1 2017 | -228 | Reduce 0.08% | 286,572 | $273.42 |
| Q4 2016 | -19,300 | Reduce 6.31% | 286,800 | $283.58 |
| Q3 2016 | +77,100 | Add 33.67% | 306,100 | $313.03 |
| Q2 2016 | +229,000 | New Buy | 229,000 | $241.82 |
HOTCHKIS & WILEY's Biogen Investment FAQs
HOTCHKIS & WILEY first purchased Biogen Inc. (BIIB) in Q2 2016, acquiring 229,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY has held Biogen Inc. (BIIB) for 28 quarters since Q2 2016.
HOTCHKIS & WILEY's largest addition to Biogen Inc. (BIIB) was in Q3 2026, adding 672,530 shares worth $151.91 M.
According to the latest 13F filing for Q3 2026, HOTCHKIS & WILEY's firm, Hotchkis & Wiley Capital Management LLC, owns 672,530 shares of Biogen Inc. (BIIB), valued at approximately $151.91 M.
As of the Q3 2026 filing, Biogen Inc. (BIIB) represents approximately 0.43% of HOTCHKIS & WILEY's publicly disclosed stock portfolio, making it one of their key holdings.
HOTCHKIS & WILEY's peak holding in Biogen Inc. (BIIB) was 672,530 shares, as reported at the end of Q3 2026.